A health care testing company focused on quicker diagnosis of women's pelvic and gynecologic infections has closed $10 million in Series A funding.
Nanopath Inc. said the funding will support development and commercialization of its biosensing platform, which it says has the potential to simultaneously test for multiple pathogens based on presenting symptoms and reduce delivery time of test results from days to just 15 minutes.
"Nanopath's mission is deeply rooted in improving women's health and,…
